2-ethyl-5-methoxynaphthalene | 2865-33-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-ethyl-5-methoxynaphthalene
• 英文别名: 2-Ethyl-5-methoxy-naphthalin；2-Ethyl-5-methoxynaphthalin；6-Ethyl-1-methoxynaphthalene
• CAS: 2865-33-0
• 化学式: C₁₃H₁₄O
• 分子量: 186.254
• InChiKey: IQCOLXZFZNHGLA-UHFFFAOYSA-N

物化性质

• 熔点：
  26.5-27.5 °C
• 沸点：
  122 °C(Press: 3 Torr)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethyl-5-methoxynaphthalene 在 溴 、 sodium acetate 作用下， 以 氯仿 为溶剂， 生成 4-Brom-6-ethyl-1-methoxy-naphthalin
  参考文献：
  名称：

  Horii,Z. et al., Chemical and pharmaceutical bulletin, 1968, vol. 16, # 12, p. 2456 - 2462

  摘要：

  DOI：
• 作为产物：
  描述：

  2-Ethyl-5-methoxy-1,2-dihydro-naphthalin 在 sulfur 作用下， 生成 2-ethyl-5-methoxynaphthalene
  参考文献：
  名称：

  Synthetic Studies on η-Pyrromycinone II. Synthesis of Methyl 2-Ethyl-5-Hydroxy-1-naphthoate

  摘要：

  作为η-吡咯霉素酮（I）合成研究的一部分，我们通过图 1 和图 2 所示的一系列反应合成了 2-乙基-5-羟基-1-萘甲酸甲酯（II，R=OH）。通过化学和核磁光谱证据讨论了作为制备中间体获得的四氢萘酮衍生物的立体化学性质。

  DOI：

  10.1248/cpb.13.651

文献信息

• [EN] (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE (PIPÉRIDIN-3-YL)(NAPHTALÉN-2-YL)MÉTHANONE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE L'HISTONE DÉMÉTHYLASE KDM2B POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2016112284A1

  公开（公告）日：2016-07-14

  The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and discloses methods of using said compositions in the treatment of cancer, such as lung cancer, leukemia or lymphoma.

  本发明涉及（哌啶-3-基）（萘-2-基）甲酮衍生物和相关化合物，作为一种或多种组蛋白去甲基酶抑制剂，如KDM2b。该发明还提供了包括本发明化合物的药学上可接受的组合物，并公开了使用该类组合物治疗癌症，如肺癌、白血病或淋巴瘤的方法。
• Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof
  申请人：Gangjee Aleem

  公开号：US20140303188A1

  公开（公告）日：2014-10-09

  The present invention provides substituted cyclopenta and cyclopentyl pyrimidine bicyclic compounds of Formula III, and 5,6-saturated and unsaturated and pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.

  本发明提供了式III的取代环戊基和环戊基嘧啶双环化合物，以及5,6-饱和和不饱和的药物可接受的盐、前药、溶剂化合物和水合物，具有抗有丝分裂活性、抗多药耐药活性，例如P-糖蛋白抑制作用和抗肿瘤活性，并且抑制紫杉醇敏感和耐药的肿瘤细胞。还提供了利用这些化合物治疗肿瘤细胞和抑制癌细胞有丝分裂的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180022727A1

  公开（公告）日：2018-01-25

  The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] AGONISTES DE GLUCAGON/ANTAGONISTES INVERSES
  申请人：NOVO NORDISK AS

  公开号：WO2002040445A1

  公开（公告）日：2002-05-23

  A novel class of compounds of the general formula (I): wherein B is (1), (2), (3) or (4), Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromaic ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, E is (a), (b), (c), (d), (e), (f), (g) or (h), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.